Abstract
Unlike the more commonly used diuretics, aquaretic agents can induce an increase in urinary volume without incurring a loss of electrolytes. These molecules belong to a family of vasopressin receptor antagonists, V2 in particular, that regulate optional renal water re-absorption via the synthesis and expression of aquaporin-2. In view of their properties, they have become the agent of choice in the treatment of hyponatremic states with water retention, and different studies have demonstrated that they are more effective and practical to use than other traditional approaches in the treatment of diseases such as cirrhosis-related ascites, SIADH and, above all, heart failure. However, the future probably holds the promise of new and unexpected applications for this type of drug in the treatment of several conditions, including polycystic kidney and glomerular disease, glaucoma and Menieres syndrome.
Keywords: Aquaretic, hyponatremia, heart failure, vasopressin, V2 antagonists
Current Pharmaceutical Design
Title: Aquaretic Agents: Whats Beyond the Treatment of Hyponatremia?
Volume: 13 Issue: 8
Author(s): Davide Bolignano, Giuseppe Coppolino, Manila Criseo, Susanna Campo, Adolfo Romeo and Michele Buemi
Affiliation:
Keywords: Aquaretic, hyponatremia, heart failure, vasopressin, V2 antagonists
Abstract: Unlike the more commonly used diuretics, aquaretic agents can induce an increase in urinary volume without incurring a loss of electrolytes. These molecules belong to a family of vasopressin receptor antagonists, V2 in particular, that regulate optional renal water re-absorption via the synthesis and expression of aquaporin-2. In view of their properties, they have become the agent of choice in the treatment of hyponatremic states with water retention, and different studies have demonstrated that they are more effective and practical to use than other traditional approaches in the treatment of diseases such as cirrhosis-related ascites, SIADH and, above all, heart failure. However, the future probably holds the promise of new and unexpected applications for this type of drug in the treatment of several conditions, including polycystic kidney and glomerular disease, glaucoma and Menieres syndrome.
Export Options
About this article
Cite this article as:
Bolignano Davide, Coppolino Giuseppe, Criseo Manila, Campo Susanna, Romeo Adolfo and Buemi Michele, Aquaretic Agents: Whats Beyond the Treatment of Hyponatremia?, Current Pharmaceutical Design 2007; 13 (8) . https://dx.doi.org/10.2174/138161207780363040
DOI https://dx.doi.org/10.2174/138161207780363040 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: Modifying Cardiovascular Risk Factors: Acquired Topics and Emerging Concepts
Current Pharmaceutical Design Recent Drug Development Approaches in Thrombosis, Stroke and other Cardiovascular Diseases
Current Pharmaceutical Design Nanocarriers for Tracking and Treating Diseases
Current Medicinal Chemistry Inotropic and Vasoactive Drugs in Pediatric ICU
Current Drug Targets Application of G-CSF in Congestive Heart Failure Treatment
Current Cardiology Reviews Blood Pressure as a Therapeutic Target in Stroke
Current Topics in Medicinal Chemistry Potential Therapeutic Targeting of Platelet-Mediated Cellular Interactions in Atherosclerosis and Inflammation
Current Medicinal Chemistry Crystal Engineering to Design of Solids: From Single to Multicomponent Organic Materials
Mini-Reviews in Organic Chemistry Cathinone Neurotoxicity (“The “3Ms”)
Current Neuropharmacology Coronary Artery Disease in Patients with Chronic Kidney Disease: A Clinical Update
Current Cardiology Reviews Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Glucagon-Like Peptide 1 and the Cardiovascular System
Current Diabetes Reviews Mechanisms of Tumor Cell Necrosis
Current Pharmaceutical Design Novel Trends in the Treatment of Cardiovascular Disorders: Site- and Event- Selective Adenosinergic Drugs
Current Medicinal Chemistry Molecular Targets of Diabetic Cardiovascular Complications
Current Drug Targets Leishmaniasis: Current Treatment and Prospects for New Drugs and Vaccines
Current Medicinal Chemistry Mechanism of Local Anesthetic Drug Action on Voltage-Gated Sodium Channels
Current Pharmaceutical Design Recent Progress in Research on Ribosome Inactivating Proteins
Current Protein & Peptide Science Molecular Imaging to Monitor Repair of Myocardial Infarction Using Genetically Engineered Bone Marrow-Derived Mesenchymal Stem Cells
Current Gene Therapy Newer Insights in Personalized and Evidence Based Medicine- the Role of MicroRNAs
Current Pharmacogenomics and Personalized Medicine